11th European AIDS Conference / EACS

Search’n Build™

Matteo Zignol  

Facing An Epidemic of Multidrug Resistant Tuberculosis
2007-10-24 - English


Joep Lange  

HIV Treatment and Prevention: Facing the Future
2007-10-24 - English


Martin Fisher  

Switching from Combivir[CBV] (AZT/3TC) to Truvada [TVD] (Tenofovir DF/FTC) Maintains Viral Suppression, Prevents and Reverses Limb Fat Loss, and Improves Biochemical Parameters: Results of a 48 Week Randomised Study
2007-10-25 - English


Huldrych Günthard  

How to Best Sequence PI's
2007-10-25 - English


Signe Worm  

Does Diabetes Mellitus (DM) Confer a Risk or Coronary Heart Disease (CHD) Equivalent to that of prior CHD in HIV-positive Individuals?
2007-10-25 - English


Alexander Panteleev  

Frequency of Smear-positive and Drug Resistant Tuberculosis in HIV-infected atients in St. Petersburg, Russia
2007-10-25 - English


Nicoletta Orchi  

Early and Late Newly Diagnosed HIV Infections
2007-10-25 - English


Stefan Mauss  

HIV-Infection Increases Cystatin C Concentrations Leading to an Underestimation of Glomerular Filtration Rate
2007-10-25 - English


Weerawat Manosuthi  

Survival and Risk of Death among HIV-infected Patients who Diagnosed Cryptococcal Meningitis with/without Antiretroviral Therapy in a Resource-Limited Settings
2007-10-25 - English


Sharon Walmsley  

Saquinavir/r (SQV/r) BID versus Lopinavir/r (LPV/r) BID, Plus Emtricitabine/Tenofovir (FTC/TDF) QD as Initial Therapy in HIV-1-infected Patients: The Gemini Study
2007-10-25 - English


Jens Lundgren  

Should HIV Treatment Be Started Sooner?
2007-10-25 - English


Emilie Lanoy  

Improvement of Survival after a Neurological AIDS Defining Event over Time
2007-10-25 - English


Philippe Flandre  

Prognostic Factors of Virological Success in Antiretroviral-naïve Patients Receiving LPV/r Monotherapy in the MONARK Trial
2007-10-25 - English


Robert Fieldhouse  

HIV Is My Disease
2007-10-25 - English



Sandra Mueller  

Protease Inhibitor Resistance Mutations Influence Recognition of Protease by HIV-1-Specific CTL
2007-10-25 - English


Dirk Meyer-Olson  

Terminal Differentiation of HIV-specific T Cell Responses is Restricted to Distinct Clonotypes with Low CD57 Expression
2007-10-25 - English


Brian Gazzard  

Use of Indicator Diseases to Optimize Testing
2007-10-25 - English


Sandra A. Calarota  

Antigen-specific T Lymphocytes with High Proliferative Capacity Inversely Correlate with Viral Replication in Chronically Untreated HIV-1-infected Individuals
2007-10-25 - English


Anna Maria Cattelan  

Nevirapine in Combination with Atazanavir/Ritonavir as a Nucleoside-sparing Regimen in HIV-infected-antiretroviral Experienced Subjects with Sustained Virologic Suppression (NEVATA Study)
2007-10-25 - English


Gerd Fatkenheuer  

Efficacy and Safety of Maraviroc (MVC) Plus Optimized Background Therapy (OBT) in Viraemic, Antiretroviral Treatment-Experienced Patients Infected with CCR5-Tropic (R5) HIV-1 in Europe, Australia and North America (MOTIVATE 2): 48-Week Results
2007-10-25 - English


François Raffi  

When, Why and How to Change Therapy
2007-10-25 - English


Alexandra Calmy  

Incidence of Nevirapine-associated Hypersensitivity Reactions in Once Daily versus Twice Daily Regimen. A Collaborative Cohort Study
2007-10-25 - English


Vicente Estrada  

The Pro12Ala Polymorphism of Peroxisome Proliferator Activated Receptor Gene y-2 (PPAR Gamma-2) is Associated with Increased Insulin Sensitivity in HIV-infected Patients on Antiretroviral Therapy
2007-10-25 - English

Genetic factors may modulate insulin resistance in HIV patients on ART


Esteban Martinez  

Triggers to Modifying Treatment
2007-10-25 - English


Graeme Moyle  

Continuation of BID Boosted PI vs Switch to Once-daily ATV/RTV for the Management of Lipodystrophy: 24-Week Interim Analysis of Metabolic and Inflammatory Parameters of the 96-Week Multicenter, Open-label, Randomised, Prospective Real Study
2007-10-25 - English


Nicola Squillace  

Non-alcoholic Fatty Liver Disease (NAFLD) in HIV Infected Patients: Prevalence, Characteristics and Predictors
2007-10-25 - English

Factors associated to diagnosis of NAFLD in HIV infected patients


Jean Michel Molina  

HIV-1 Genotypic Resistance during Intermittent Antiretroviral Therapy and its Impact on CD4 Cell Counts and Antiviral Response. A Substudy of the ANRS 106 Window Trial
2007-10-25 - English


Srini Ramanathan  

Clinical Pharmacology of the HIV Integrase Inhibitor Elvitegravir
2007-10-25 - English


Joep Lange  

Pre-exposure Prophylaxis(PrEP): State-of-the-art
2007-10-26 - English


Marta Boffito  

Pharmacokinetics (PK) of atazanavir/ritonavir (ATV/r) once daily (OD) and lopinavir/ritonavir (LPV/r) twice daily (BD) and OD over 72 hours following drug intake cessation
2007-10-26 - English

The importance of half life and drug persistance when advising HIV patients on once daily regimens


Esteban Martinez  

Clinical Case 2 - Naive ART Patient with Marginal Increased Risk of CVD
2007-10-26 - English


Stefan Mauss  

Clinical Case 1 - Hepatitis B
2007-10-26 - English


Jürgen Rockstroh  

Introduction to Hepatitis Treatment Guidelines
2007-10-26 - English


Vincent Soriano  

New Drugs on the Horizon for Treatment of Viral Hepatitis
2007-10-26 - English



Jan Van Lunzen  

ARTEMIS: Efficacy and safety of lopinavir (BID vs QD) and darunavir (QD) in antiretroviral-naïve patients
2007-10-26 - English


Bernard Hirschel  

Growing Old with HIV
2007-10-26 - English


 Cristina Mussini  

Patient case: 2nd failure to ARV therapy
2007-10-26 - English



Elisabeth Aslangul  

A prospective, randomized, open label trial comparing the efficacy and safety of rosuvastatin versus pravastatin in HIV-infected subjects receiving ritonavir boosted PI with lipid abnormalities.
2007-10-26 - English


Steven Grinspoon  

Long-Term Safety and Efficacy of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor (GRF) Analogue, in HIV-Infected Patients with Abdominal Fat Accumulation
2007-10-26 - English


Thomas Harrer  

A Randomized, Controlled, Phase II Study with an MVA-nef Vaccine in HIV-1 Infected Patients Followed by Structured Treatment Interruption (STI)
2007-10-26 - English

Objective: MVA-BN, a viral vector which is safe and fails to replicate in human cells, has shown potent ability to induce cell mediated immune response in previous phase I/II studies. This phase II trial was initiated to assess the immunogenicity and safety of the...(more)







 Bertran Auvert  

Male Circumcision
2007-10-26 - English


Giuseppe Pantaleo  

HIV Vaccines: State-of-the-art
2007-10-26 - English


Jacqueline Capeau  

Does HIV Therapy Affect Normal Aging?
2007-10-27 - English


Christian Hoffmann  

Cancer and HIV: What Does the Future Hold?
2007-10-27 - English


William Powderly  

Assessing and Managing CVD in HIV
2007-10-27 - English